JAZZ vs XERS · P/E 1988, rev $2.28B vs rev $175.2M
Jazz Pharmaceuticals PLC (JAZZ) versus Xeris Pharmaceuticals Inc (XERS) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Xeris Pharmaceuticals Inc (XERS) is a biotechnology company listed on US.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported XERS revenue for 2026-06-30 was $175.2M. Net income was -$28.9M. XERS currently screens at market cap $760.7M.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. XERS currently screens at market cap $760.7M.
Not investment advice. Open the JAZZ and XERS stock pages for the full models.
Not investment advice.